By John Leavitt, Ph.D. Nerac Analyst
Originally Published: July 21, 2014
Over the past two decades I have been somewhat amused by the seemingly abrupt emergence of the fields called “genomics” and “proteomics” and all of the other “…omics”. Read more
When Did Proteomics Begin?
The Revolution in Next Generation Nucleic Acid Sequencing: How is it profoundly changing biology and medicine?
By Stephen Buxser, Ph.D. Nerac Analyst
Originally Published: July 21, 2014
A revolution is well underway in the development and application of new nucleic acid sequencing technologies. Read more
A Brief History of Monoclonal Antibodies
By John Leavitt, Ph.D. Nerac Analyst
Originally Published: July 21, 2014
When I saw an obit for Hilary Koprowski recently, I was surprised that it did not mention his benchmark work with “monoclonal antibodies” or “hybridomas.” Read more
The Cloning of Human Embryonic Stem Cells…and Human Beings?
By John Leavitt, Ph.D. Nerac Analyst
Originally Published July 21, 2014
Recently we read in the NY Times of a successful cloning of human embryonic stem cells by Oregon Health and Sciences University researchers led by Professor Shoukhrat Mitalipov. Read more
The Holy Grail of Cancer Research – A Protein That Enables Aggressive Tumor Growth and Metastasis
By John Leavitt, Ph.D. Nerac Analyst
Originally Published July 21, 2014
Such a protein appears to be described in a paper published in the journal Molecular Cancer Therapeutics in February 2014 by Heinz-Josef Lenz at the Keck School of Medicine of the University of Southern California in collaboration with colleagues at the University of Graz in Austria. Read more
Environmental Responsibility in Cosmetics: The Case of Microbeads
By Stephenie Smulligan-Maldanis, Nerac Analyst
Brilliant, white teeth and clear skin: it seems like Americans are in constant pursuit of youth and beauty. Read more
The Costs of Regulatory Noncompliance in the Medical Device Industry: Is it Worth the Gamble?
By Donna Mitchell-Magaldi, Nerac Analyst,
The global medical device market was valued at $350 billion dollars in 2012 (Mddonline.com, 2012).
Read more